NasdaqGS:OLMABiotechs
Assessing Olema Pharmaceuticals (OLMA) Valuation After Wider Q1 Loss And Late‑Stage Trial Updates
Olema Pharmaceuticals (OLMA) shares are trading after first quarter results showed a net loss of US$53.09 million, with management emphasizing higher clinical spending, upcoming Phase 3 palazestrant data, and preparations for a possible commercial launch.
See our latest analysis for Olema Pharmaceuticals.
At a share price of US$13.82, Olema has seen its short term share price return fall 15.21% over the past month and 45.33% year to date, even as the 1 year total shareholder return is very...